Objective        To observe the clinical efficacy and safety of single intravitreal injection of anti-vascular endothelial growth factor (VEGF) agent

lucentis

for refractory macular edema after cataract surgery.     Methods       Nine patients (10 eyes)with refractory macular edema after cataract surgery (phacoemulsification combined with intraocular lens implantation)at our department from July 2014 to July 2015 were included in the study. All patients had medical history of refractory macular edema longer than 3 months

confirmed by examinations of optical coherence tomography (OCT) and fundus fluorescein angiography (FFA). Macular edema caused by other macular-related disease were excluded

and patients had no any systemic and local operation contraindication. The central foveal thickness(CFT) before treatment were 480±121 μm. For the affected eyes

single intravitreal injection of lucentis 0.5 mg（0.05 mL）was administrated. Follow-up period continued for 12 weeks. The changes of visual acuity (VA)

intraocular pressure

OCT and FFA were compared before and after the treatment.   Results       The VA of 9 patients (10 eyes) was obviously improved in 1 week after treatment

with stable vision at the 4 and 12 weeks. The VA differences between the pre- and after lucentis injection were statistically significant（P0.01）. For the CFT measured by OCT

it dropped to 293±58 μm in 1 week after therapy

with the thickness of 231±23 μm and 235±35 μm at the 4 and 12 weeks

respectively. The differences of CFT before and after treatment were also statistically significant. Meanwhile

no patients experienced ocular or systemic adverse reactions.   Conclusion        Intravitreal injection of lucentis for refractory macular edema after cataract surgery can significantly improve the patients’ visual function

and reduce macular edema with no side effect observed.